Leerink Global Healthcare Conference 2025 March 10, 2025 11:20 AM ETCompany ParticipantsAlisha Alaimo - President of ...
Pharmaceutical Technology on MSN1d
Vaccinex plans Nasdaq exit as Alzheimer market pressure growsAs with many early-stage companies, Vaccinex funnelled the majority of its resources into a lead candidate. The asset, called ...
An appointment with Wendell Helveston, M.D., a neurologist in Hattiesburg, MS, led to a series of diagnostic tests, such as ...
NICE is seeking public comment on the updated draft guidances through March 27, with plans to issue final draft guidances in July.
Biogen, Eisai’s Leqembi Suffers Overseas Setbacks as UK Denies Coverage, Australia Denies Approval
Days after suffering a rejection in Australia, the Alzheimer’s drug hit another roadblock in the U.K., which found the drug ...
England’s National Institute for Health and Care Excellence (NICE) has given a second thumbs down to a pair of Alzheimer’s ...
Systematic fraud -- led by a "cabal of self-interested researchers, government accomplices, and corporate greed" in the words ...
The U.K has released a huge repository of children’s genomic data after sequencing blood samples from three large cohorts recruited at birth and followed across three decades. The power of the data is ...
Japanese drugmaker Eisai Inc. will lay off 57 employees in Nutley between the end of March and May, public records show, as the pharmaceutical company shaves off 7% of its U.S workforce.
Leqembi’s application now moves forward to the European Commission, which will issue a formal verdict for the injection that ...
St. Charles, Missouri, resident Sue Bell became one of the first Alzheimer's patients in the U.S. to receive the drug now ...
The European Union’s medicines regulator on Friday reiterated its positive recommendation for Eisai and Biogen’s Alzheimer’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback